FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
By Lori Solomon HealthDay Reporter
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.
Capvaxive is specifically designed to help protect adults against the serotypes that cause the majority of invasive pneumococcal disease cases, including Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B, in individuals ages 18 year and older, and for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years and older.
The priority review was based on the pivotal phase 3 STRIDE-3 trial, which compared Capvaxive to pneumococcal 20-valent conjugate vaccine in adults ages 18 years and older, who had not previously received a pneumococcal vaccine, as well as the phase 3 STRIDE-5 and STRIDE-6 trials, which evaluated Capvaxive in vaccine-naive and vaccine-experienced adults. Capvaxive includes eight unique serotypes not covered by other currently approved pneumococcal vaccines, but that are responsible for approximately 27 percent of invasive pneumococcal disease cases in adults ages 50 years and older and approximately 30 percent of cases in adults ages 65 years and older, according to epidemiological data. The company says the vaccine covers serotypes responsible for approximately 84 percent of invasive pneumococcal disease in adults ages 50 years and older.
"Today's approval is a testament to our population-specific strategy behind Capvaxive, which demonstrated robust immunogenicity in a range of adult populations and is driven by a deep understanding of pneumococcal disease," Dean Y. Li, M.D., Ph.D., from Merck Research Laboratories, said in a statement. "We are proud to provide Capvaxive as a new option specifically designed to help protect against the majority of invasive pneumococcal disease-causing serotypes in adults."
Approval of Capvaxive was granted to Merck.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
CDC Provides Update on Measles Outbreak in the United States
TUESDAY, April 29, 2025 -- Eight hundred cases of measles were reported in the United States as of April 17, 2025, representing the second highest annual case count in 25 years...
Older Adults Have Low Knowledge of RSV Disease and Vaccine Eligibility
MONDAY, April 7, 2025 -- Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.